Oppenheimer Weighs in on CymaBay Therapeutics Inc’s FY2019 Earnings (NASDAQ:CBAY)

CymaBay Therapeutics Inc (NASDAQ:CBAY) – Investment analysts at Oppenheimer cut their FY2019 earnings estimates for shares of CymaBay Therapeutics in a research report issued on Tuesday, November 5th. Oppenheimer analyst J. Olson now anticipates that the biopharmaceutical company will post earnings of ($1.48) per share for the year, down from their prior forecast of ($1.44). Oppenheimer also issued estimates for CymaBay Therapeutics’ Q4 2019 earnings at ($0.38) EPS, FY2021 earnings at ($1.36) EPS, FY2022 earnings at ($0.70) EPS and FY2023 earnings at $0.42 EPS.

CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01).

CBAY has been the subject of a number of other reports. BidaskClub raised CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 23rd. Cantor Fitzgerald set a $20.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Evercore ISI reaffirmed a “buy” rating and set a $15.00 price objective on shares of CymaBay Therapeutics in a research note on Wednesday, August 14th. Zacks Investment Research cut CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, ValuEngine raised CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. CymaBay Therapeutics has an average rating of “Buy” and a consensus price target of $13.25.

CBAY opened at $5.93 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.20 and a current ratio of 16.20. CymaBay Therapeutics has a 52-week low of $4.23 and a 52-week high of $14.00. The business’s 50-day simple moving average is $4.98 and its 200 day simple moving average is $7.50. The firm has a market capitalization of $356.56 million, a PE ratio of -4.71 and a beta of 1.25.

In other CymaBay Therapeutics news, CEO Sujal Shah bought 5,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was purchased at an average cost of $5.53 per share, with a total value of $27,650.00. Following the completion of the purchase, the chief executive officer now owns 111,900 shares in the company, valued at $618,807. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders acquired 11,900 shares of company stock valued at $59,600. Insiders own 4.20% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC acquired a new position in CymaBay Therapeutics in the third quarter valued at about $61,000. SG Americas Securities LLC bought a new stake in shares of CymaBay Therapeutics in the third quarter valued at about $85,000. Assenagon Asset Management S.A. bought a new stake in shares of CymaBay Therapeutics in the third quarter valued at about $1,037,000. University of Notre Dame DU Lac bought a new stake in shares of CymaBay Therapeutics in the second quarter valued at about $2,043,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of CymaBay Therapeutics in the second quarter valued at about $80,000. 98.81% of the stock is owned by hedge funds and other institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: How does a security become overbought?

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.